Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced o1/07/96 \ \ Origin: Appendix 5 \ \ Amended o1/07/98, o1/09/99, o1/07/00, 30/09/01, 11/03/02, o1/01/03, 24/10/05, o1/08/12, o4/03/13$

Ellex Medical Lasers Limited							
ABN							
15 007	702 927						
We (tł	We (the entity) give ASX the following information.						
Part 1 - All issues You must complete the relevant sections (attach sheets if there is not enough space).							
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary shares					
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	6,500,000 (from the placement announced 7 th April 2016)					
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares					

Appendix 3B Page 1

Name of entity

 $[\]scriptstyle +$ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Ordinary shares - Yes
5	Issue price or consideration	\$0.77
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	 Support a range of initiatives related to iTrack, Asia geographical expansion and product development. Providing working capital to the company generally.
ба	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder	N/A
	resolution under rule 7.1A was passed	
6c	Number of *securities issued	N/A
	without security holder approval under rule 7.1	

Appendix 3B Page 2

04/03/2013

⁺ See chapter 19 for defined terms.

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
бе	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	·
6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
бh	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	N/A	
7	+Issue dates	Placement - 13 th April	2016
•	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	Number 114,146,897 (being the current shares on issue and the	⁺ Class Fully paid ordinary shares

shares)

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and ⁺ class of all	Nil	-
	+securities not quoted on ASX		
	(including the ⁺ securities in section 2 if applicable)		
	section 2 if applicable)		
			 -
10	Dividend policy (in the case of a trust, distribution policy) on		
	the increased capital (interests)		
	(
Part	2 - Pro rata issue		
11	Is security holder approval		
	required?		:
12	Is the issue renounceable or non-		
12	renounceable?		
13	Ratio in which the *securities		
	will be offered		
1.4	⁺ Class of ⁺ securities to which the		
14	offer relates		'
15	⁺ Record date to determine		
	entitlements		
-6	MATERIA DE LA JECCO .		
16	Will holdings on different registers (or subregisters) be		
	aggregated for calculating		
	entitlements?		
17	Policy for deciding entitlements in relation to fractions		
	in relation to fractions		
18	Names of countries in which the		
	entity has security holders who		
	will not be sent new offer		
	documents		
	Note: Security holders must be told how their entitlements are to be dealt with.		:
	Cross reference: rule 7.7.		

Appendix 3B Page 4 04/03/2013

⁺ See chapter 19 for defined terms.

19	Closing	date	for	receipt	of				
acceptances or renunciations									

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

20	Names of any underwriters	
	L	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements in full through a broker?	
31	How do security holders sell part of their entitlements through a broker and accept for the balance?	

Appendix 3B Page 6 04/03/2013

⁺ See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	⁺ Issue	e date	
	-	Quotation of securities complete this section if you are app	
34	Type (tick o	of ⁺ securities one)	
(a)		⁺ Securities described in Part 1	
(b)			of the escrowed period, partly paid securities that become fully paid, restriction ends, securities issued on expiry or conversion of convertible
Entitie	es tha	t have ticked box 34(a)	
Addit	ional	securities forming a new	class of securities
Tick to docume		e you are providing the informatio	n or
35			securities, the names of the 20 largest holders of and the number and percentage of additional ers
36			ecurities, a distribution schedule of the additional nber of holders in the categories
37		A copy of any trust deed for the	he additional ⁺ securities

04/03/2013

⁺ See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought		
39	⁺ Class of ⁺ securities for which quotation is sought	·	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another *security, clearly identify that other *security)		
42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	⁺ Class

Appendix 3B Page 8 04/03/2013

⁺ See chapter 19 for defined terms.

Quotation agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before [†]quotation of the [†]securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Company secretary

Date: 13th April 2016

Print name:

Maria Maieli

+ See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page 9

== == == == ==